508.460.8822 Contact Us

Proveris Laboratories announces the availability of services utilizing a new approach to IVIVC (In-Vitro / In-Vivo Correlation) for inhalation drug products

May 24th, 2019 | Posted in Proveris News

Hudson, MA, May 24, 2019 – Proveris Scientific Corporation, a leading provider of services and technology to advance the science of respiratory drug delivery products, today announced the addition of new services to accelerate product characterization, performance, safety and bioequivalence testing of inhalation drug products by measuring the aerosolization process, regional deposition and bioavailability under more human realistic conditions than existing methods.

These services are aligned with recent efforts to establish in-vitro/in-vivo correlation (IVIVC) and support the FDA’s newly released draft guidance on Beclomethasone Dipropionate that promotes alternate in-vitro studies in lieu of clinical endpoint.

Based on an innovative new proprietary technology, these services have been developed in collaboration with key industry leaders and are now being offered through Proveris Labs.

“We are very excited to offer our customers access to this new technology” comments Alberto Correia, Vice President of Technical Services, “we believe we will provide our customers tremendous insight into the performance of their products and enable a new approach to IVIVC.”

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis while leveraging their expertise, experience and core technologies. With customers’ success as their central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” that include product innovation, technical services, systems, consumables and educational training.

Since its founding in 1995, the company has accelerated the development of the top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc. and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit www.proveris.com.

December 11, 2019 | Edinburgh, Scotland
MVIS Symposium
October 7, 2019 | Lund, Sweden
Inhalation Asia 2019
November 13, 2019 | Hong Kong

View all upcoming events

"Proveris Scientific Corporation provides expert support for nasal developers. They are fast, reliable and are professionals at installing of their equipment and supports in demanding challenges." Dr. Peter Svete, Head of Physical Analytics, Lek Pharmaceuticals d.d.
"Proveris provides insightful and thorough test services. We would recommend working with Proveris. Proveris has great expertise in spray analysis." Elaine Schutte, Chief Development Officer, ProFibrix
"I want to express my sincere gratitude towards Proveris and the service team for being there to make sure our study goes well. The study just completed few minutes ago and thankfully everything went well.......while we conducted SAC study. It was a great display of professionalism by Proveris." ,
"As customary, Proveris's service team provided excellent service and was able to answer my questions." ,
"Thank you for the thorough training on our new equipment. I wish more companies would implement your hands on approach when it comes to training. Thanks again." ,
“We really appreciate the creativity and work conducted at Proveris for their Test Services (Proveris by Design®). Their knowledge, experience, and insight with OINDP’s was very helpful. Thanks to the Proveris team, we have a wonderful solution that we can use for commercial products!” Mic Iwashima, NDS Division, Shin Nippon Biomedical Laboratories, Ltd